Works matching AU Baskoy, Gozde
Results: 5
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes.
- Published in:
- Diabetes Care, 2024, v. 47, n. 4, p. 668, doi. 10.2337/dc23-1646
- By:
- Publication type:
- Article
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 944, doi. 10.1111/dom.16094
- By:
- Publication type:
- Article
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 1033, doi. 10.1111/dom.15404
- By:
- Publication type:
- Article
Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2024, v. 109, n. 1, p. 161, doi. 10.1210/clinem/dgad438
- By:
- Publication type:
- Article